BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 21349414)

  • 21. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New and emerging syndromes due to neuroendocrine tumors.
    Vinik AI; Gonzales MR
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine tumor disease: an evolving landscape.
    Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
    Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory tests for neuroendocrine tumours.
    Seregni E; Ferrari L; Stivanello M; Dogliotti L
    Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach.
    Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB
    Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
    Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
    Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical diagnosis of gastroenteropancreatic endocrine tumors.
    Tartaglia A; Bianchini S; Vezzadini P
    Minerva Med; 2003 Feb; 94(1):1-7. PubMed ID: 12719697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of biomarker tests for diagnosis of neuroendocrine tumours.
    Hofland J; Zandee WT; de Herder WW
    Nat Rev Endocrinol; 2018 Nov; 14(11):656-669. PubMed ID: 30158549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine tumors of the luminal gastrointestinal tract.
    Grin A; Streutker CJ
    Arch Pathol Lab Med; 2015 Jun; 139(6):750-6. PubMed ID: 26030244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
    Kim JY; Hong SM
    Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limitations of Chromogranin A in clinical practice.
    Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
    Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Foreword: Gastroenteropancreatic system and its tumors: Part 1.
    LeRoith D
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xiii-xvi. PubMed ID: 21095537
    [No Abstract]   [Full Text] [Related]  

  • 38. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
    Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
    Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
    de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
    Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical testing for neuroendocrine tumors.
    Vinik AI; Silva MP; Woltering EA; Go VL; Warner R; Caplin M
    Pancreas; 2009 Nov; 38(8):876-89. PubMed ID: 19855234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.